F-18 FES PET / CT in Measuring Hormone Expression in Patients with Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

Status: Enrolling by Invitation

Description

This clinical trial studies use of F-18 16 alpha-fluoroestradiol ([F-18] FES) positron emission tomography (PET) / computed tomography (CT) in measuring tumor hormone receptor expression in patients undergoing endocrine-targeted therapy for newly diagnosed breast cancer or breast cancer that has come back or spread to other places in the body. Comparing results of diagnostic procedures done before, during, and after hormone therapy may help measure a patient's response to treatment.

Eligibility Criteria

Inclusion Criteria

  • Adult, non-pregnant patients with biopsy-proven or clinically obvious primary, recurrent or metastatic breast cancer
  • Breast cancer from ER+ primary that is seen on other imaging tests; tumor ER expression must have been confirmed by immunohistocytochemistry of primary tumor or recurrent disease
  • At least one site of disease 1.5 cm or greater is needed to meet the spatial resolution limits of PET imaging
  • Patients must have been off tamoxifen or other estrogen receptor blocking agents for at least 6 weeks and off chemotherapy for 3 weeks for the initial baseline FES
  • Patients must be selected for an endocrine targeted therapy regimen for treatment of their breast cancer by the referring oncologist; selected treatments may be part of experimental treatment protocols for which the patient would be separately consented
  • Patients must be willing to undergo serial imaging procedures
  • Patients must agree to allow access to clinical records regarding response to treatment and long term follow up

Exclusion Criteria

  • An inability to lie still for the tests
  • Individuals weighing more than 300 lb; (this is the weight limit of the scanner table)
  • Pregnant or lactating; women of childbearing potential with either a positive or no pregnancy test at baseline are excluded
  • Any other life-threatening illness (e.g. serious, uncontrolled concurrent infection or clinically significant cardiac disease – congestive heart failure, symptomatic coronary artery disease, cardiac arrhythmia not well controlled with medication)
  • Use of tamoxifen, Faslodex, diethylstilbestrol (DES) or any other ER blocking agent < 6 weeks or chemotherapy < 3 weeks prior to imaging scan
  • Unwillingness or inability to give informed consent
  • Uncontrolled diabetes mellitus (fasting glucose > 200 mg/dL)
  • Adult patients who require monitored anesthesia for PET scanning

Locations & Contacts

Washington

Seattle
Fred Hutch / University of Washington Cancer Consortium
Status: Enrolling by invitation
Contact: Hannah Margaret Linden
Phone: 206-606-6710
Email: hmlinden@u.washington.edu

Trial Objectives and Outline

PRIMARY OBJECTIVES:

I. Measure the effect of endocrine targeted therapy on estrogen receptor (ER) expression and estradiol binding to the receptor using serial FES PET and fludeoxyglucose F-18 (FDG) PET.

SECONDARY OBJECTIVES:

I. Document the safety profile of FES PET in patients with breast cancer.

II. Examine associations between FES PET results and serial measurements of hormone or other levels in peripheral blood, as related to efficacy of endocrine-targeted therapy. Correlate FES PET uptake measures with histopathological assays and tumor microenvironment studies on biopsy specimens, if relevant to specific treatment regimen.

OUTLINE:

Patients undergo F-18 FES PET/CT scan at baseline. Patients also undergo F-18 FES PET/CT and FDG PET/CT between 1-12 weeks after starting therapy, and then 1-12 weeks after the second FES PET/CT scan. Repeat FDG PET may be omitted in patients on selective estrogen receptor degrader.

After completion of study, patients are followed up for up to 20 years.

Trial Phase & Type

Trial Phase

No phase specified

Trial Type

Diagnostic

Lead Organization

Lead Organization
Fred Hutch / University of Washington Cancer Consortium

Principal Investigator
Hannah Margaret Linden

Trial IDs

Primary ID 7184
Secondary IDs NCI-2013-02342
Clinicaltrials.gov ID NCT02149173